A multicenter, randomized, double-blind, placebo-controlled clinical study evaluating the efficacy and safety of Opicapone in primary Parkinson's disease patients with fluctuating end-of-life motor symptoms after treatment with levodopa/dopamine decarboxylase inhibitors (ChiCTR) - Oct 16, 2026 - P3 | N=250 | Completed | Sponsor: Ruijin Hospital, Shanghai Jiaotong University School of Medicine; Shanghai Fosun Pharmaceutical (Group) Co., Ltd | Not yet recruiting ➔ Completed
Trial completion • CNS Disorders • Movement Disorders • Parkinson's Disease
|